Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 70518-1781

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-1781). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 250mg 70518 1781 01

The packaging label for Divalproex Sodium 250 mg extended-release film-coated tablets displays a quantity of 100 tablets. The label indicates the product is repackaged by RemedyRepack Inc. and manufactured by Aurobindo Pharma, Dayton, NJ. Directions for use specify consulting the package insert and storage instructions are included.*

FDA Label Image

Divalproex Sodium 250mg 70518 1781 02

Divalproex Sodium 250 mg extended-release film-coated tablet label showing quantity of 1 tablet. The label includes NDC number 70518-1781-02, manufacturer Aurobindo Pharma Dayton, NJ, and repackaging information by RemedyRepack Inc., Indiana, PA. Directions advise to see package insert; storage conditions and a QR code are also present.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Divalproex Sodium extended-release film-coated tablets, 250 mg strength. The package contains 30 tablets. It is repackaged by RemedyRepack Inc. and directs to see the package insert for directions. The label includes storage instructions and manufacturing information from Aurobindo Pharma, Dayton, NJ.*

FDA Label Image

Figure 1 (Divalproex Fig1)

A cumulative response curve chart comparing Divalproex Sodium Delayed-Release Tablets with placebo. The x-axis shows the percentage of patients, and the y-axis shows the percentage reduction in CPS rate, indicating improvement or worsening. The solid line represents Divalproex Sodium, and the dashed line represents the placebo.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A Kaplan-Meier type curve graph showing the percentage reduction in CPS Rate on the vertical axis versus the percentage of patients on the horizontal axis for high and low dose divalproex sodium delayed-release tablets. The graph compares treatment outcomes, illustrating improvement or worsening among patients taking different doses of this oral extended-release tablet.*

FDA Label Image

Figure-3 (Divalproex Fig3)

A bar chart comparing two groups labeled as Placebo and Divalproex Sodium Extended-Release Tablets. The vertical axis represents a numerical scale from 0 to 1.2, with the Placebo bar approximately at 0.6 and the Divalproex Sodium bar at about 1.2, indicating a statistical significance noted by p=0.006.*

FDA Label Image

Structure (Divalproex Str)

Chemical structure of divalproex sodium, showing its molecular components and arrangement including sodium ion and carbon chains consistent with its chemical formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.